Aflibercept in macular oedema: added benefit not proven

Neither the new drug nor the comparator therapy was used in accordance with their approvals in the studiesFor the third time in one year, the German Institute for Quality and Efficiency in Health Care (IQWiG) dealt with the drug aflibercept.